IDL Diagnostics AB (publ) (STO:IDLDX)

Market Cap	80.86M -28.2%
Revenue (ttm)	53.11M -7.5%
Net Income	-12.15M
EPS	-0.05
Shares Out	230.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,801
Average Volume	132,124
Open	0.3500
Previous Close	0.3740
Day's Range	0.3500 - 0.3650
52-Week Range	0.2500 - 0.6200
Beta	0.70
RSI	52.56
Earnings Date	Apr 22, 2026

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 20
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IDLDX

Financial Performance

In 2025, IDL Diagnostics AB's revenue was 53.11 million, a decrease of -7.54% compared to the previous year's 57.44 million. Losses were -12.15 million, -71.38% less than in 2024.